Pharmaceutical products

Tender description

Transition and 33 % products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months). NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months).